Table 2 Experience with clinical therapeutic trials among gastroenterologists and hepatologists*
From: Factors influencing the participation of gastroenterologists and hepatologists in clinical research
Experience | Gastroenterologists (n = 160) | Hepatologists (n = 189) |
|---|---|---|
Number of clinical trials in the previous 12 months | Â | Â |
   0 | 65 (40.6)‡ | 48 (25.4)‡ |
   1 to 4 | 70 (43.8) | 89 (47.1) |
   5 to 10 | 17 (10.6)‡ | 43 (22.8)‡ |
   > 10 | 7 (4.4) | 8 (4.2) |
Number of clinical trials in the previous 5 years | Â | Â |
   0 | 44 (27.5)‡ | 34 (18.0)‡ |
   1 to 4 | 40 (25.0) | 34 (18.0) |
   5 to 10 | 35 (21.9) | 42 (22.2) |
   > 10 | 40 (25.0)‡ | 79 (41.8)‡ |
Types of clinical trials | Â | Â |
   Drug trials (human studies) | 112 (42.9) | 149 (57.1) |
   Basic science research | 28 (17.5)‡ | 51 (27.0)‡ |
   Non-drug trials (eg, procedural) | 39 (24.4) | 53 (28.0) |
   Non-drug epidemiological research | 51 (31.9)‡ | 102 (54.0)‡ |
   Other | 1 (0.6) | 3 (1.6) |
Sources of funding for clinical trials | Â | Â |
   Pharmaceutical company | 107 (66.9)‡ | 144 (76.2)‡ |
   Government institutions | 54 (33.8)‡ | 96 (50.8)‡ |
   Nongovernmental, charitable, or philanthropic organization | 15 (9.4)‡ | 49 (25.9)‡ |
   University or hospital funding | 55 (34.4)‡ | 92 (48.7)‡ |
   Other | 1 (0.6) | 2 (1.1) |
Most preferred funding source†|  |  |
   Pharmaceutical company | 52 (44.8) | 79 (50.1) |
   Government institution | 46 (41.1) | 59 (37.8) |
   Nongovernmental, charitable, or philanthropic organization | 13 (12.2) | 10 (7.0) |
   University or hospital funding | 7 (6.4) | 12 (8.1) |
   Other | 0 (0.0) | 1 (3.2) |